Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Dermira Inc.
Public Company Edition: Outside the US, Zai Lab raised more in its recent Hong Kong initial public offering – $766.4m – than PMV, Prelude, Taysha, Graybug and Greenwich combined. Also, Gilead priced debt to fund its $21bn Immunomedics buy and ADC Therapeutics raised $204m.
Public Company Edition: The former Allergan CEO is taking a special purpose acquisition corporation public to generate $460m for deals in familiar biopharma niches. Also, IPOs are expected to keep up a robust pace in the fall and Albireo raises $160m on the success of its drug for pediatric liver diseases.
Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.
News and views from day four of BIO Digital also include discussion of whether the pandemic is discouraging mega mergers.
- Specialty Pharmaceuticals
- Topical Delivery
- Large Molecule
- Other Names / Subsidiaries
- Valocor Therapeutics, Inc.